FIASP

Peak

insulin aspart injection

BLAINTRAVENOUS, SUBCUTANEOUSSOLUTION
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
15

Mechanism of Action

metabolism. Insulins, including insulin aspart, the active ingredient in FIASP, exert their specific action through binding to insulin receptors. Receptor-bound insulin lowers blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and by inhibiting the…

Pharmacologic Class:

Insulin Analog

Clinical Trials (5)

NCT05069545N/ACompleted

A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice

Started Oct 2021
411 enrolled
Diabetes Mellitus, Type 1
NCT03987802N/ACompleted

An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice

Started Jan 2021
42 enrolled
Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
NCT04460326Phase 3Completed

Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus

Started Dec 2020
137 enrolled
Type 2 Diabetes Treated With Insulin
NCT03895515N/ACompleted

Effect of Fiasp® in Type 1 Diabetes Treatment

Started Jan 2020
178 enrolled
Diabetes Mellitus, Type 1
NCT03450863N/ACompleted

Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device

Started Mar 2018
320 enrolled
DiabetesDiabetes Mellitus, Type 1 Diabetes